Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participat...
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
A director at Haulotte Group bought 14,068 shares at 2.162EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.